|
Yes
þ
|
No
o
|
Yes
þ
|
No
o
|
Yes
o
|
No
þ
|
|
|
Page
|
||
PART I - FINANCIAL INFORMATION
|
|
||
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|||
|
|
|
|
|
|||
|
|
|
|
|
|||
|
|
||
PART II - OTHER INFORMATION
|
|
||
|
|
|
|
|
|||
|
|
|
|
|
|||
|
|
|
|
|
|||
|
|
|
|
|
|||
|
|
||
Item 1.
|
FINANCIAL STATEMENTS
|
|
Quarter Ended June 30
|
|
Year to Date Ended June 30
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Net Revenue
|
|
|
|
|
|
|
|
||||||||
Product sales and service
|
$
|
593.1
|
|
|
$
|
556.0
|
|
|
$
|
1,714.6
|
|
|
$
|
1,650.4
|
|
Rental revenue
|
96.0
|
|
|
99.4
|
|
|
290.8
|
|
|
298.8
|
|
||||
Total revenue
|
689.1
|
|
|
655.4
|
|
|
2,005.4
|
|
|
1,949.2
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Cost of Revenue
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of goods sold
|
311.5
|
|
|
293.6
|
|
|
905.6
|
|
|
896.0
|
|
||||
Rental expenses
|
46.5
|
|
|
46.4
|
|
|
141.7
|
|
|
142.9
|
|
||||
Total cost of revenue
|
358.0
|
|
|
340.0
|
|
|
1,047.3
|
|
|
1,038.9
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Gross Profit
|
331.1
|
|
|
315.4
|
|
|
958.1
|
|
|
910.3
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Research and development expenses
|
34.9
|
|
|
33.6
|
|
|
102.2
|
|
|
101.5
|
|
||||
Selling and administrative expenses
|
221.0
|
|
|
209.9
|
|
|
652.2
|
|
|
640.5
|
|
||||
Special charges (Note 8)
|
34.8
|
|
|
13.7
|
|
|
43.7
|
|
|
31.5
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Operating Profit
|
40.4
|
|
|
58.2
|
|
|
160.0
|
|
|
136.8
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Interest expense
|
(23.8
|
)
|
|
(23.0
|
)
|
|
(65.2
|
)
|
|
(68.2
|
)
|
||||
Investment income and other, net
|
(0.5
|
)
|
|
0.1
|
|
|
(2.1
|
)
|
|
0.6
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Income Before Income Taxes
|
16.1
|
|
|
35.3
|
|
|
92.7
|
|
|
69.2
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Income tax expense (benefit) (Note 9)
|
10.4
|
|
|
(9.7
|
)
|
|
29.5
|
|
|
(2.2
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Net Income
|
5.7
|
|
|
45.0
|
|
|
63.2
|
|
|
71.4
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Less: Net loss attributable to noncontrolling interests
|
(0.3
|
)
|
|
(0.3
|
)
|
|
(1.0
|
)
|
|
(1.0
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Net Income Attributable to Common Shareholders
|
$
|
6.0
|
|
|
$
|
45.3
|
|
|
$
|
64.2
|
|
|
$
|
72.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net Income Attributable to Common Shareholders per Common Share - Basic
|
$
|
0.09
|
|
|
$
|
0.69
|
|
|
$
|
0.98
|
|
|
$
|
1.11
|
|
|
|
|
|
|
|
|
|
||||||||
Net Income Attributable to Common Shareholders per Common Share - Diluted
|
$
|
0.09
|
|
|
$
|
0.68
|
|
|
$
|
0.95
|
|
|
$
|
1.09
|
|
|
|
|
|
|
|
|
|
||||||||
Dividends per Common Share
|
$
|
0.18
|
|
|
$
|
0.17
|
|
|
$
|
0.53
|
|
|
$
|
0.50
|
|
|
|
|
|
|
|
|
|
||||||||
Average Common Shares Outstanding - Basic (thousands) (Note 10)
|
65,795
|
|
|
65,406
|
|
|
65,567
|
|
|
65,300
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Average Common Shares Outstanding - Diluted (thousands) (Note 10)
|
67,688
|
|
|
66,552
|
|
|
67,300
|
|
|
66,402
|
|
|
Quarter Ended
June 30 |
|
Year to Date Ended June 30
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Net Income
|
$
|
5.7
|
|
|
$
|
45.0
|
|
|
$
|
63.2
|
|
|
$
|
71.4
|
|
|
|
|
|
|
|
|
|
||||||||
Other Comprehensive Income, net of tax (Note 7):
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Available-for-sale securities and hedges
|
(2.4
|
)
|
|
(3.3
|
)
|
|
7.6
|
|
|
(5.0
|
)
|
||||
Foreign currency translation adjustment
|
38.1
|
|
|
(20.1
|
)
|
|
12.6
|
|
|
(17.7
|
)
|
||||
Change in pension and postretirement defined benefit plans
|
0.6
|
|
|
0.9
|
|
|
2.7
|
|
|
2.2
|
|
||||
Total Other Comprehensive Income (Loss), net of tax
|
36.3
|
|
|
(22.5
|
)
|
|
22.9
|
|
|
(20.5
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Total Comprehensive Income
|
42.0
|
|
|
22.5
|
|
|
86.1
|
|
|
50.9
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Less: Comprehensive loss attributable to noncontrolling interests
|
(0.3
|
)
|
|
(0.3
|
)
|
|
(1.0
|
)
|
|
(1.0
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Total Comprehensive Income Attributable to Common Shareholders
|
$
|
42.3
|
|
|
$
|
22.8
|
|
|
$
|
87.1
|
|
|
$
|
51.9
|
|
|
June 30,
2017 |
|
September 30,
2016 |
||||
ASSETS
|
|
|
|
||||
Current Assets
|
|
|
|
||||
Cash and cash equivalents
|
$
|
243.2
|
|
|
$
|
232.2
|
|
Trade accounts receivable, net of allowances (Note 2)
|
519.4
|
|
|
515.1
|
|
||
Inventories (Note 2)
|
268.1
|
|
|
252.0
|
|
||
Other current assets
|
80.8
|
|
|
82.8
|
|
||
Total current assets
|
1,111.5
|
|
|
1,082.1
|
|
||
|
|
|
|
||||
Property, plant and equipment, net (Note 2)
|
354.8
|
|
|
350.0
|
|
||
Goodwill (Note 4)
|
1,751.6
|
|
|
1,584.4
|
|
||
Other intangible assets and software, net (Note 2)
|
1,170.2
|
|
|
1,143.3
|
|
||
Deferred income taxes (Notes 1 and 9)
|
42.7
|
|
|
43.1
|
|
||
Other assets
|
53.3
|
|
|
59.5
|
|
||
Total Assets
|
$
|
4,484.1
|
|
|
$
|
4,262.4
|
|
|
|
|
|
||||
LIABILITIES
|
|
|
|
|
|
||
Current Liabilities
|
|
|
|
|
|
||
Trade accounts payable
|
$
|
143.5
|
|
|
$
|
136.0
|
|
Short-term borrowings (Note 5)
|
187.4
|
|
|
210.1
|
|
||
Accrued compensation
|
119.1
|
|
|
127.0
|
|
||
Accrued product warranties (Note 12)
|
26.9
|
|
|
27.5
|
|
||
Accrued rebates
|
39.8
|
|
|
40.8
|
|
||
Other current liabilities
|
116.0
|
|
|
120.9
|
|
||
Total current liabilities
|
632.7
|
|
|
662.3
|
|
||
|
|
|
|
||||
Long-term debt (Note 5)
|
2,151.5
|
|
|
1,938.4
|
|
||
Accrued pension and postretirement benefits (Note 6)
|
99.6
|
|
|
99.0
|
|
||
Deferred income taxes (Notes 1 and 9)
|
270.2
|
|
|
287.8
|
|
||
Other long-term liabilities
|
38.9
|
|
|
39.0
|
|
||
Total Liabilities
|
3,192.9
|
|
|
3,026.5
|
|
||
|
|
|
|
||||
Commitments and Contingencies (Note 14)
|
|
|
|
|
|
||
|
|
|
|
||||
SHAREHOLDERS' EQUITY
|
|
|
|
|
|
||
Common Stock (Note 2)
|
4.4
|
|
|
4.4
|
|
||
Additional paid-in capital
|
587.0
|
|
|
575.9
|
|
||
Retained earnings
|
1,618.7
|
|
|
1,589.7
|
|
||
Accumulated other comprehensive loss (Note 7)
|
(146.2
|
)
|
|
(169.1
|
)
|
||
Treasury stock, at cost (Note 2)
|
(780.4
|
)
|
|
(773.7
|
)
|
||
Total Shareholders' Equity Attributable to Common Shareholders
|
1,283.5
|
|
|
1,227.2
|
|
||
Noncontrolling interests
|
7.7
|
|
|
8.7
|
|
||
Total Shareholders' Equity
|
1,291.2
|
|
|
1,235.9
|
|
||
Total Liabilities and Shareholders' Equity
|
$
|
4,484.1
|
|
|
$
|
4,262.4
|
|
(In millions)
|
Year to Date Ended June 30
|
||||||
|
2017
|
|
2016
|
||||
Operating Activities
|
|
|
|
||||
Net income
|
$
|
63.2
|
|
|
$
|
71.4
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
||
Depreciation
|
60.5
|
|
|
71.9
|
|
||
Amortization
|
15.3
|
|
|
12.9
|
|
||
Acquisition-related intangible asset amortization
|
80.2
|
|
|
72.1
|
|
||
Provision for deferred income taxes
|
(23.3
|
)
|
|
(7.9
|
)
|
||
Loss on disposal of property, equipment leased to others, intangible assets, and impairments
|
23.5
|
|
|
1.4
|
|
||
Gain on sale of businesses
|
(1.0
|
)
|
|
—
|
|
||
Stock compensation
|
17.5
|
|
|
18.1
|
|
||
Excess tax benefits from employee stock plans
|
—
|
|
|
(1.3
|
)
|
||
Change in working capital excluding cash, current debt, acquisitions and dispositions:
|
|
|
|
|
|
||
Trade accounts receivable
|
13.7
|
|
|
33.5
|
|
||
Inventories
|
(1.8
|
)
|
|
11.8
|
|
||
Other current assets
|
13.2
|
|
|
16.5
|
|
||
Trade accounts payable
|
1.0
|
|
|
(15.3
|
)
|
||
Accrued expenses and other liabilities
|
(29.9
|
)
|
|
(79.0
|
)
|
||
Other, net
|
7.6
|
|
|
(0.7
|
)
|
||
Net cash provided by operating activities
|
239.7
|
|
|
205.4
|
|
||
Investing Activities
|
|
|
|
|
|
||
Capital expenditures and purchases of intangible assets
|
(73.8
|
)
|
|
(60.7
|
)
|
||
Proceeds on sale of property and equipment leased to others
|
13.7
|
|
|
1.5
|
|
||
Payment for acquisition of businesses, net of cash acquired
|
(311.4
|
)
|
|
—
|
|
||
Proceeds on sale of businesses
|
4.5
|
|
|
0.5
|
|
||
Other
|
(2.1
|
)
|
|
(1.6
|
)
|
||
Net cash used in investing activities
|
(369.1
|
)
|
|
(60.3
|
)
|
||
Financing Activities
|
|
|
|
|
|
||
Proceeds from borrowings on long-term debt
|
300.0
|
|
|
2.5
|
|
||
Payment of long-term debt
|
(54.9
|
)
|
|
(109.9
|
)
|
||
Borrowings on Revolving Credit Facility
|
108.0
|
|
|
20.0
|
|
||
Payments on Revolving Credit Facility
|
(248.8
|
)
|
|
(20.0
|
)
|
||
Borrowings on Securitization Program
|
101.3
|
|
|
—
|
|
||
Payments on Securitization Program
|
(14.5
|
)
|
|
—
|
|
||
Debt issuance costs
|
(5.1
|
)
|
|
—
|
|
||
Purchase of noncontrolling interest of former joint venture
|
—
|
|
|
(0.4
|
)
|
||
Payment of cash dividends
|
(34.8
|
)
|
|
(32.6
|
)
|
||
Proceeds on exercise of stock options
|
17.5
|
|
|
3.8
|
|
||
Proceeds from stock issuance
|
3.5
|
|
|
2.7
|
|
||
Excess tax benefits from employee stock plans
|
—
|
|
|
1.3
|
|
||
Treasury stock acquired
|
(34.3
|
)
|
|
(3.5
|
)
|
||
Net cash provided by (used in) financing activities
|
137.9
|
|
|
(136.1
|
)
|
||
Effect of exchange rate changes on cash
|
2.5
|
|
|
(2.2
|
)
|
||
Net Cash Flows
|
11.0
|
|
|
6.8
|
|
||
Cash and Cash Equivalents:
|
|
|
|
|
|
||
At beginning of period
|
232.2
|
|
|
192.8
|
|
||
At end of period
|
$
|
243.2
|
|
|
$
|
199.6
|
|
•
|
Level 1: Financial instruments with unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets and liabilities.
|
•
|
Level 2: Financial instruments with observable inputs other than those included in Level 1 such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
|
•
|
Level 3: Financial instruments with unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Unobservable inputs reflect our own assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). Unobservable inputs are developed based on the best information available in the circumstances, which might include our own data.
|
|
June 30,
2017 |
|
September 30,
2016 |
||||
Allowance for possible losses and discounts on trade receivables
|
$
|
28.2
|
|
|
$
|
26.8
|
|
|
|
|
|
||||
Inventories:
|
|
|
|
|
|
||
Finished products
|
$
|
144.5
|
|
|
$
|
124.2
|
|
Raw materials and work in process
|
123.6
|
|
|
127.8
|
|
||
Total inventory
|
$
|
268.1
|
|
|
$
|
252.0
|
|
|
|
|
|
||||
Accumulated depreciation of property, plant and equipment
|
$
|
615.9
|
|
|
$
|
611.8
|
|
|
|
|
|
||||
Accumulated amortization of software and other intangible assets
|
$
|
480.8
|
|
|
$
|
398.3
|
|
|
|
|
|
||||
Preferred stock, without par value:
|
|
|
|
|
|
||
Shares authorized
|
1,000,000
|
|
|
1,000,000
|
|
||
Shares issued
|
None
|
|
|
None
|
|
||
|
|
|
|
||||
Common stock, without par value:
|
|
|
|
|
|
||
Shares authorized
|
199,000,000
|
|
|
199,000,000
|
|
||
Shares issued
|
88,457,634
|
|
|
88,457,634
|
|
||
Shares outstanding
|
65,879,595
|
|
|
65,705,253
|
|
||
|
|
|
|
||||
Treasury shares
|
22,578,039
|
|
|
22,752,381
|
|
|
Amount
|
||
Trade receivables
|
$
|
16.4
|
|
Inventory
|
21.3
|
|
|
Other current assets
|
2.8
|
|
|
Property, plant and equipment
|
18.1
|
|
|
Goodwill
|
165.5
|
|
|
Trade names (7-year weighted average useful life)
|
15.8
|
|
|
Customer relationships (8-year useful life)
|
37.8
|
|
|
Developed technology (7-year useful life)
|
53.6
|
|
|
Other noncurrent assets
|
3.8
|
|
|
Current liabilities
|
(22.6
|
)
|
|
Noncurrent liabilities
|
(1.3
|
)
|
|
Total purchase price, net of cash acquired
|
$
|
311.2
|
|
|
Patient Support Systems
|
|
Front Line Care
|
|
Surgical Solutions
|
|
Total
|
||||||||
Balances at September 30, 2016
|
|
|
|
|
|
|
|
||||||||
Goodwill
|
$
|
544.1
|
|
|
$
|
1,205.5
|
|
|
$
|
307.6
|
|
|
$
|
2,057.2
|
|
Accumulated impairment losses
|
(472.8
|
)
|
|
—
|
|
|
—
|
|
|
(472.8
|
)
|
||||
Goodwill, net at September 30, 2016
|
71.3
|
|
|
1,205.5
|
|
|
307.6
|
|
|
1,584.4
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Changes in Goodwill during the period:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Goodwill related to acquisitions
|
(1.2
|
)
|
|
165.5
|
|
|
—
|
|
|
164.3
|
|
||||
Currency translation effect
|
0.5
|
|
|
1.5
|
|
|
0.9
|
|
|
2.9
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Balances at June 30, 2017
|
|
|
|
|
|
|
|
|
|
|
|
||||
Goodwill
|
543.4
|
|
|
1,372.5
|
|
|
308.5
|
|
|
2,224.4
|
|
||||
Accumulated impairment losses
|
(472.8
|
)
|
|
—
|
|
|
—
|
|
|
(472.8
|
)
|
||||
Goodwill, net at June 30, 2017
|
$
|
70.6
|
|
|
$
|
1,372.5
|
|
|
$
|
308.5
|
|
|
$
|
1,751.6
|
|
|
June 30,
2017 |
|
September 30,
2016 |
||||
Revolving credit facilities
|
$
|
95.0
|
|
|
$
|
235.8
|
|
Current portion of long-term debt
|
100.5
|
|
|
73.2
|
|
||
Senior secured Term Loan A, long-term portion
|
1,293.1
|
|
|
1,372.3
|
|
||
Senior unsecured 5.75% notes due on September 1, 2023
|
419.7
|
|
|
419.1
|
|
||
Senior unsecured 5.00% notes due on February 14, 2025
|
295.6
|
|
|
—
|
|
||
Unsecured 7.00% debentures due on February 15, 2024
|
13.6
|
|
|
13.7
|
|
||
Unsecured 6.75% debentures due on December 15, 2027
|
29.6
|
|
|
29.6
|
|
||
Securitization Program
|
86.8
|
|
|
—
|
|
||
Other
|
5.0
|
|
|
4.8
|
|
||
Total debt
|
2,338.9
|
|
|
2,148.5
|
|
||
Less Short-term borrowings
|
187.4
|
|
|
210.1
|
|
||
Total Long-term debt
|
$
|
2,151.5
|
|
|
$
|
1,938.4
|
|
•
|
$1,462.5 million
senior secured Term Loan A facility (“TLA Facility”), maturing in
September 2021
|
•
|
Revolving Credit Facility, providing borrowing capacity of up to
$700.0 million
, maturing in
September 2021
|
Fiscal Quarter Ended
|
Maximum
Secured Net Leverage Ratio |
Minimum
Interest Coverage Ratio |
December 31, 2016
|
4.50x
|
3.25x
|
December 31, 2017
|
4.00x
|
3.50x
|
December 31, 2018
|
3.50x
|
3.75x
|
December 31, 2019 and thereafter
|
3.00x
|
4.00x
|
|
June 30,
2017 |
|
September 30,
2016 |
||||
Senior secured Term Loan A
|
$
|
1,392.9
|
|
|
$
|
1,441.0
|
|
Senior unsecured 5.75% notes due on September 1, 2023
|
449.6
|
|
|
454.0
|
|
||
Senior unsecured 5.00% notes due on February 14, 2025
|
307.4
|
|
|
—
|
|
||
Unsecured debentures
|
44.9
|
|
|
45.8
|
|
||
Total debt
|
$
|
2,194.8
|
|
|
$
|
1,940.8
|
|
|
Quarter Ended June 30
|
|
Year to Date Ended June 30
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Service cost
|
$
|
1.4
|
|
|
$
|
1.3
|
|
|
$
|
4.3
|
|
|
$
|
3.8
|
|
Interest cost
|
2.5
|
|
|
2.8
|
|
|
7.4
|
|
|
8.2
|
|
||||
Expected return on plan assets
|
(3.7
|
)
|
|
(3.3
|
)
|
|
(11.0
|
)
|
|
(9.8
|
)
|
||||
Amortization of unrecognized prior service cost, net
|
—
|
|
|
0.1
|
|
|
0.1
|
|
|
0.2
|
|
||||
Amortization of net loss
|
1.5
|
|
|
1.1
|
|
|
4.6
|
|
|
3.4
|
|
||||
Net pension expense
|
$
|
1.7
|
|
|
$
|
2.0
|
|
|
$
|
5.4
|
|
|
$
|
5.8
|
|
|
Quarter Ended June 30, 2017
|
||||||||||||||||||||||||||||||
|
Other comprehensive income (loss)
|
|
Accumulated other comprehensive income (loss)
|
||||||||||||||||||||||||||||
|
Prior to
reclassification
|
|
Reclassification
from
|
|
Pre-tax
|
|
Tax effect
|
|
Net of tax
|
|
Beginning
balance
|
|
Net activity
|
|
Ending
balance
|
||||||||||||||||
Available-for-sale securities and hedges
|
$
|
(3.5
|
)
|
|
$
|
(0.2
|
)
|
|
$
|
(3.7
|
)
|
|
$
|
1.3
|
|
|
$
|
(2.4
|
)
|
|
$
|
6.9
|
|
|
$
|
(2.4
|
)
|
|
$
|
4.5
|
|
Foreign currency translation adjustment
|
37.1
|
|
|
1.0
|
|
|
38.1
|
|
|
—
|
|
|
38.1
|
|
|
(140.7
|
)
|
|
38.1
|
|
|
(102.6
|
)
|
||||||||
Change in pension and postretirement defined benefit plans
|
(0.5
|
)
|
|
1.5
|
|
|
1.0
|
|
|
(0.4
|
)
|
|
0.6
|
|
|
(48.7
|
)
|
|
0.6
|
|
|
(48.1
|
)
|
||||||||
Total
|
$
|
33.1
|
|
|
$
|
2.3
|
|
|
$
|
35.4
|
|
|
$
|
0.9
|
|
|
$
|
36.3
|
|
|
$
|
(182.5
|
)
|
|
$
|
36.3
|
|
|
$
|
(146.2
|
)
|
|
Quarter Ended June 30, 2016
|
||||||||||||||||||||||||||||||
|
Other comprehensive income (loss)
|
|
Accumulated other comprehensive income (loss)
|
||||||||||||||||||||||||||||
|
Prior to
reclassification
|
|
Reclassification
from
|
|
Pre-tax
|
|
Tax effect
|
|
Net of tax
|
|
Beginning
balance
|
|
Net activity
|
|
Ending
balance
|
||||||||||||||||
Available-for-sale securities and hedges
|
$
|
(5.5
|
)
|
|
$
|
0.4
|
|
|
$
|
(5.1
|
)
|
|
$
|
1.8
|
|
|
$
|
(3.3
|
)
|
|
$
|
(1.7
|
)
|
|
$
|
(3.3
|
)
|
|
$
|
(5.0
|
)
|
Foreign currency translation adjustment
|
(20.1
|
)
|
|
—
|
|
|
(20.1
|
)
|
|
—
|
|
|
(20.1
|
)
|
|
(90.4
|
)
|
|
(20.1
|
)
|
|
(110.5
|
)
|
||||||||
Change in pension and postretirement defined benefit plans
|
—
|
|
|
1.1
|
|
|
1.1
|
|
|
(0.2
|
)
|
|
0.9
|
|
|
(46.7
|
)
|
|
0.9
|
|
|
(45.8
|
)
|
||||||||
Total
|
$
|
(25.6
|
)
|
|
$
|
1.5
|
|
|
$
|
(24.1
|
)
|
|
$
|
1.6
|
|
|
$
|
(22.5
|
)
|
|
$
|
(138.8
|
)
|
|
$
|
(22.5
|
)
|
|
$
|
(161.3
|
)
|
|
Year to Date Ended June 30, 2017
|
||||||||||||||||||||||||||||||
|
Other comprehensive income (loss)
|
|
Accumulated other comprehensive income (loss)
|
||||||||||||||||||||||||||||
|
Prior to
reclassification |
|
Reclassification
from |
|
Pre-tax
|
|
Tax effect
|
|
Net of tax
|
|
Beginning
balance |
|
Net activity
|
|
Ending
balance |
||||||||||||||||
Available-for-sale securities and hedges
|
$
|
13.1
|
|
|
$
|
(0.9
|
)
|
|
$
|
12.2
|
|
|
$
|
(4.6
|
)
|
|
$
|
7.6
|
|
|
$
|
(3.1
|
)
|
|
$
|
7.6
|
|
|
$
|
4.5
|
|
Foreign currency translation adjustment
|
11.6
|
|
|
1.0
|
|
|
12.6
|
|
|
—
|
|
|
12.6
|
|
|
(115.2
|
)
|
|
12.6
|
|
|
(102.6
|
)
|
||||||||
Change in pension and postretirement defined benefit plans
|
(0.1
|
)
|
|
4.4
|
|
|
4.3
|
|
|
(1.6
|
)
|
|
2.7
|
|
|
(50.8
|
)
|
|
2.7
|
|
|
(48.1
|
)
|
||||||||
Total
|
$
|
24.6
|
|
|
$
|
4.5
|
|
|
$
|
29.1
|
|
|
$
|
(6.2
|
)
|
|
$
|
22.9
|
|
|
$
|
(169.1
|
)
|
|
$
|
22.9
|
|
|
$
|
(146.2
|
)
|
|
Year to Date Ended June 30, 2016
|
||||||||||||||||||||||||||||||
|
Other comprehensive income (loss)
|
|
Accumulated other comprehensive income (loss)
|
||||||||||||||||||||||||||||
|
Prior to
reclassification
|
|
Reclassification
from
|
|
Pre-tax
|
|
Tax effect
|
|
Net of tax
|
|
Beginning
balance
|
|
Net activity
|
|
Ending
balance
|
||||||||||||||||
Available-for-sale securities and hedges
|
$
|
(8.1
|
)
|
|
$
|
0.4
|
|
|
$
|
(7.7
|
)
|
|
$
|
2.7
|
|
|
$
|
(5.0
|
)
|
|
$
|
—
|
|
|
$
|
(5.0
|
)
|
|
$
|
(5.0
|
)
|
Foreign currency translation adjustment
|
(17.7
|
)
|
|
—
|
|
|
(17.7
|
)
|
|
—
|
|
|
(17.7
|
)
|
|
(92.8
|
)
|
|
(17.7
|
)
|
|
(110.5
|
)
|
||||||||
Change in pension and postretirement defined benefit plans
|
—
|
|
|
3.2
|
|
|
3.2
|
|
|
(1.0
|
)
|
|
2.2
|
|
|
(48.0
|
)
|
|
2.2
|
|
|
(45.8
|
)
|
||||||||
Total
|
$
|
(25.8
|
)
|
|
$
|
3.6
|
|
|
$
|
(22.2
|
)
|
|
$
|
1.7
|
|
|
$
|
(20.5
|
)
|
|
$
|
(140.8
|
)
|
|
$
|
(20.5
|
)
|
|
$
|
(161.3
|
)
|
|
Quarter Ended June 30
|
||||||||||||||||||||||
|
2017
|
|
2016
|
||||||||||||||||||||
|
Amount
reclassified |
|
Tax effect
|
|
Net of tax
|
|
Amount
reclassified
|
|
Tax effect
|
|
Net of tax
|
||||||||||||
Available-for-sale securities and hedges (a)
|
$
|
(0.2
|
)
|
|
$
|
—
|
|
|
$
|
(0.2
|
)
|
|
$
|
0.4
|
|
|
$
|
(0.2
|
)
|
|
$
|
0.2
|
|
Foreign currency translation adjustment (b)
|
$
|
1.0
|
|
|
$
|
—
|
|
|
$
|
1.0
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Change in pension and postretirement defined benefit plans (c)
|
$
|
1.5
|
|
|
$
|
(0.5
|
)
|
|
$
|
1.0
|
|
|
$
|
1.1
|
|
|
$
|
(0.2
|
)
|
|
$
|
0.9
|
|
|
Year to Date Ended June 30
|
||||||||||||||||||||||
|
2017
|
|
2016
|
||||||||||||||||||||
|
Amount
reclassified
|
|
Tax effect
|
|
Net of tax
|
|
Amount
reclassified
|
|
Tax effect
|
|
Net of tax
|
||||||||||||
Available-for-sale securities and hedges (a)
|
$
|
(0.9
|
)
|
|
$
|
0.2
|
|
|
$
|
(0.7
|
)
|
|
$
|
0.4
|
|
|
$
|
(0.2
|
)
|
|
$
|
0.2
|
|
Foreign currency translation adjustment (b)
|
$
|
1.0
|
|
|
$
|
—
|
|
|
$
|
1.0
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Change in pension and postretirement defined benefit plans (c)
|
$
|
4.4
|
|
|
$
|
(1.6
|
)
|
|
$
|
2.8
|
|
|
$
|
3.2
|
|
|
$
|
(1.0
|
)
|
|
$
|
2.2
|
|
Balance at September 30, 2016
|
$
|
14.7
|
|
Expenses
|
7.3
|
|
|
Cash Payments
|
(10.4
|
)
|
|
Reversals
|
(0.8
|
)
|
|
Balance at June 30, 2017
|
$
|
10.8
|
|
|
Quarter Ended June 30
|
|
Year to Date Ended June 30
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Net income attributable to common shareholders
|
$
|
6.0
|
|
|
$
|
45.3
|
|
|
$
|
64.2
|
|
|
$
|
72.4
|
|
|
|
|
|
|
|
|
|
||||||||
Average shares outstanding - Basic
|
65,795
|
|
|
65,406
|
|
|
65,567
|
|
|
65,300
|
|
||||
Add potential effect of exercise of stock options
and other unvested equity awards
|
1,893
|
|
|
1,146
|
|
|
1,733
|
|
|
1,102
|
|
||||
Average shares outstanding - Diluted
|
67,688
|
|
|
66,552
|
|
|
67,300
|
|
|
66,402
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Net income attributable to common shareholders per common share - Basic
|
$
|
0.09
|
|
|
$
|
0.69
|
|
|
$
|
0.98
|
|
|
$
|
1.11
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Net income attributable to common shareholders per common share - Diluted
|
$
|
0.09
|
|
|
$
|
0.68
|
|
|
$
|
0.95
|
|
|
$
|
1.09
|
|
|
|
|
|
|
|
|
|
||||||||
Shares with anti-dilutive effect excluded from the computation of Diluted EPS
|
2
|
|
|
557
|
|
|
225
|
|
|
502
|
|
|
Quarter Ended June 30
|
|
Year to Date Ended June 30
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Balance at beginning of period
|
$
|
27.4
|
|
|
$
|
28.8
|
|
|
$
|
27.5
|
|
|
$
|
32.1
|
|
Provision for warranties during the period
|
4.0
|
|
|
3.5
|
|
|
10.3
|
|
|
11.3
|
|
||||
Warranty reserves acquired
|
—
|
|
|
—
|
|
|
1.9
|
|
|
—
|
|
||||
Warranty claims during the period
|
(4.5
|
)
|
|
(5.3
|
)
|
|
(12.8
|
)
|
|
(16.4
|
)
|
||||
Balance at end of period
|
$
|
26.9
|
|
|
$
|
27.0
|
|
|
$
|
26.9
|
|
|
$
|
27.0
|
|
•
|
Patient Support Systems –
globally sells and rents our specialty frames and surfaces and mobility solutions, as well as our clinical workflow solutions.
|
•
|
Front Line Care –
globally sells and rents respiratory care products, and sells medical diagnostic equipment and a diversified portfolio of devices that assess, diagnose, treat, and manage a wide variety of illnesses and diseases.
|
•
|
Surgical Solutions –
globally sells products that improve surgical safety and efficiency in the operating room including tables, lights, pendants, positioning devices and various other safety and accessory products.
|
|
Quarter Ended
June 30 |
|
Year to Date Ended June 30
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Revenue:
|
|
|
|
|
|
|
|
||||||||
Patient Support Systems
|
$
|
354.7
|
|
|
$
|
361.0
|
|
|
$
|
1,052.8
|
|
|
$
|
1,054.9
|
|
Front Line Care
|
227.1
|
|
|
192.7
|
|
|
639.9
|
|
|
598.2
|
|
||||
Surgical Solutions
|
107.3
|
|
|
101.7
|
|
|
312.7
|
|
|
296.1
|
|
||||
Total revenue
|
$
|
689.1
|
|
|
$
|
655.4
|
|
|
$
|
2,005.4
|
|
|
$
|
1,949.2
|
|
|
|
|
|
|
|
|
|
||||||||
Divisional income:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Patient Support Systems
|
$
|
62.8
|
|
|
$
|
65.0
|
|
|
$
|
174.1
|
|
|
$
|
168.0
|
|
Front Line Care
|
56.4
|
|
|
47.5
|
|
|
160.3
|
|
|
143.2
|
|
||||
Surgical Solutions
|
8.7
|
|
|
10.6
|
|
|
26.0
|
|
|
30.9
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Other operating costs:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Non-allocated operating costs, administrative costs, and other
|
52.7
|
|
|
51.2
|
|
|
156.7
|
|
|
173.8
|
|
||||
Special charges
|
34.8
|
|
|
13.7
|
|
|
43.7
|
|
|
31.5
|
|
||||
Operating profit
|
40.4
|
|
|
58.2
|
|
|
160.0
|
|
|
136.8
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Interest expense
|
(23.8
|
)
|
|
(23.0
|
)
|
|
(65.2
|
)
|
|
(68.2
|
)
|
||||
Investment income and other, net
|
(0.5
|
)
|
|
0.1
|
|
|
(2.1
|
)
|
|
0.6
|
|
||||
Income before income taxes
|
$
|
16.1
|
|
|
$
|
35.3
|
|
|
$
|
92.7
|
|
|
$
|
69.2
|
|
Item 2.
|
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
|
•
|
Patient Support Systems –
globally sells and rents our specialty frames and surfaces and mobility solutions, as well as our clinical workflow solutions.
|
•
|
Front Line Care –
globally sells and rents respiratory care products, and sells medical diagnostic equipment and a diversified portfolio of devices that assess, diagnose, treat, and manage a wide variety of illnesses and diseases.
|
•
|
Surgical Solutions –
globally sells products that improve surgical safety and efficiency in the operating room including tables, lights, pendants, positioning devices and various other safety and accessory products.
|
|
|
|
|
|
|
|
|
|
U.S.
|
|
OUS
|
|||||||||||
|
Quarter Ended
June 30 |
|
Change As
Reported
|
|
Constant
Currency
|
|
Change As
Reported
|
|
Change As
Reported
|
|
Constant
Currency
|
|||||||||||
|
2017
|
|
2016
|
|
|
|
|
|
||||||||||||||
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Product sales and service
|
$
|
593.1
|
|
|
$
|
556.0
|
|
|
6.7
|
%
|
|
7.6
|
%
|
|
6.1
|
%
|
|
7.8
|
%
|
|
10.5
|
%
|
Rental revenue
|
96.0
|
|
|
99.4
|
|
|
(3.4
|
)%
|
|
(2.9
|
)%
|
|
(2.4
|
)%
|
|
(11.0
|
)%
|
|
(6.8
|
)%
|
||
Total revenue
|
$
|
689.1
|
|
|
$
|
655.4
|
|
|
5.1
|
%
|
|
6.0
|
%
|
|
4.4
|
%
|
|
6.8
|
%
|
|
9.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Patient Support Systems
|
$
|
354.7
|
|
|
$
|
361.0
|
|
|
(1.7
|
)%
|
|
(1.1
|
)%
|
|
(1.4
|
)%
|
|
(2.5
|
)%
|
|
(0.2
|
)%
|
Front Line Care
|
227.1
|
|
|
192.7
|
|
|
17.9
|
%
|
|
18.8
|
%
|
|
17.0
|
%
|
|
20.2
|
%
|
|
23.6
|
%
|
||
Surgical Solutions
|
107.3
|
|
|
101.7
|
|
|
5.5
|
%
|
|
7.0
|
%
|
|
—
|
%
|
|
11.5
|
%
|
|
14.6
|
%
|
||
Total revenue
|
$
|
689.1
|
|
|
$
|
655.4
|
|
|
5.1
|
%
|
|
6.0
|
%
|
|
4.4
|
%
|
|
6.8
|
%
|
|
9.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
OUS - Outside of the U.S.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
U.S.
|
|
OUS
|
|||||||||||
|
Year to Date Ended
June 30 |
|
Change As
Reported
|
|
Constant
Currency
|
|
Change As
Reported
|
|
Change As
Reported
|
|
Constant
Currency
|
|||||||||||
|
2017
|
|
2016
|
|
|
|
|
|
||||||||||||||
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Product sales and service
|
$
|
1,714.6
|
|
|
$
|
1,650.4
|
|
|
3.9
|
%
|
|
4.8
|
%
|
|
5.1
|
%
|
|
1.7
|
%
|
|
4.3
|
%
|
Rental revenue
|
290.8
|
|
|
298.8
|
|
|
(2.7
|
)%
|
|
(2.1
|
)%
|
|
(1.8
|
)%
|
|
(9.3
|
)%
|
|
(4.8
|
)%
|
||
Total revenue
|
$
|
2,005.4
|
|
|
$
|
1,949.2
|
|
|
2.9
|
%
|
|
3.8
|
%
|
|
3.7
|
%
|
|
1.0
|
%
|
|
3.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Patient Support Systems
|
$
|
1,052.8
|
|
|
$
|
1,054.9
|
|
|
(0.2
|
)%
|
|
0.5
|
%
|
|
1.1
|
%
|
|
(3.4
|
)%
|
|
(0.8
|
)%
|
Front Line Care
|
639.9
|
|
|
598.2
|
|
|
7.0
|
%
|
|
7.6
|
%
|
|
7.2
|
%
|
|
6.3
|
%
|
|
8.4
|
%
|
||
Surgical Solutions
|
312.7
|
|
|
296.1
|
|
|
5.6
|
%
|
|
7.5
|
%
|
|
7.4
|
%
|
|
3.8
|
%
|
|
7.5
|
%
|
||
Total revenue
|
$
|
2,005.4
|
|
|
$
|
1,949.2
|
|
|
2.9
|
%
|
|
3.8
|
%
|
|
3.7
|
%
|
|
1.0
|
%
|
|
3.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
OUS - Outside of the U.S.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended June 30
|
|
Year to Date Ended June 30
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Gross Profit
|
|
|
|
|
|
|
|
||||||||
Product sales and service
|
$
|
281.6
|
|
|
$
|
262.4
|
|
|
$
|
809.0
|
|
|
$
|
754.4
|
|
Percent of Related Revenue
|
47.5
|
%
|
|
47.2
|
%
|
|
47.2
|
%
|
|
45.7
|
%
|
||||
|
|
|
|
|
|
|
|
||||||||
Rental
|
49.5
|
|
|
53.0
|
|
|
149.1
|
|
|
155.9
|
|
||||
Percent of Related Revenue
|
51.6
|
%
|
|
53.3
|
%
|
|
51.3
|
%
|
|
52.2
|
%
|
||||
|
|
|
|
|
|
|
|
||||||||
Total Gross Profit
|
$
|
331.1
|
|
|
$
|
315.4
|
|
|
$
|
958.1
|
|
|
$
|
910.3
|
|
Percent of Total Revenue
|
48.0
|
%
|
|
48.1
|
%
|
|
47.8
|
%
|
|
46.7
|
%
|
|
Quarter Ended June 30
|
|
Year to Date Ended June 30
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Research and development expenses
|
$
|
34.9
|
|
|
$
|
33.6
|
|
|
$
|
102.2
|
|
|
$
|
101.5
|
|
Percent of Total Revenue
|
5.1
|
%
|
|
5.1
|
%
|
|
5.1
|
%
|
|
5.2
|
%
|
||||
|
|
|
|
|
|
|
|
||||||||
Selling and administrative expenses
|
$
|
221.0
|
|
|
$
|
209.9
|
|
|
$
|
652.2
|
|
|
$
|
640.5
|
|
Percent of Total Revenue
|
32.1
|
%
|
|
32.0
|
%
|
|
32.5
|
%
|
|
32.9
|
%
|
|
Quarter Ended
June 30 |
|
Change As
Reported
|
|
Year to Date Ended June 30
|
|
Change As
Reported
|
||||||||||||||
|
2017
|
|
2016
|
|
|
2017
|
|
2016
|
|
||||||||||||
Divisional income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Patient Support Systems
|
$
|
62.8
|
|
|
$
|
65.0
|
|
|
(3.4
|
)%
|
|
$
|
174.1
|
|
|
$
|
168.0
|
|
|
3.6
|
%
|
Front Line Care
|
56.4
|
|
|
47.5
|
|
|
18.7
|
%
|
|
160.3
|
|
|
143.2
|
|
|
11.9
|
%
|
||||
Surgical Solutions
|
8.7
|
|
|
10.6
|
|
|
(17.9
|
)%
|
|
26.0
|
|
|
30.9
|
|
|
(15.9
|
)%
|
|
Quarter Ended June 30
|
|
Year to Date Ended June 30
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Special charges
|
$
|
34.8
|
|
|
$
|
13.7
|
|
|
$
|
43.7
|
|
|
$
|
31.5
|
|
|
|
|
|
|
|
|
|
||||||||
Interest expense
|
$
|
(23.8
|
)
|
|
$
|
(23.0
|
)
|
|
$
|
(65.2
|
)
|
|
$
|
(68.2
|
)
|
Investment income and other, net
|
$
|
(0.5
|
)
|
|
$
|
0.1
|
|
|
$
|
(2.1
|
)
|
|
$
|
0.6
|
|
|
Quarter Ended June 30, 2017
|
|
Quarter Ended June 30, 2016
|
||||||||||||||||||||||||||
|
Operating
Margin 1 |
|
Income
Before Income Taxes |
|
Income Tax
Expense |
|
Diluted EPS
|
|
Operating
Margin |
|
Income
Before Income Taxes |
|
Income Tax
Expense |
|
Diluted EPS
|
||||||||||||||
GAAP Basis
|
5.9
|
%
|
|
$
|
16.1
|
|
|
$
|
10.4
|
|
|
$
|
0.09
|
|
|
8.9
|
%
|
|
$
|
35.3
|
|
|
$
|
(9.7
|
)
|
|
$
|
0.68
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Acquisition and integration costs
|
0.9
|
%
|
|
5.9
|
|
|
2.4
|
|
|
0.05
|
|
|
0.5
|
%
|
|
3.5
|
|
|
0.7
|
|
|
0.04
|
|
||||||
Acquisition-related intangible asset amortization
|
4.1
|
%
|
|
28.1
|
|
|
9.4
|
|
|
0.28
|
|
|
3.7
|
%
|
|
24.1
|
|
|
8.2
|
|
|
0.24
|
|
||||||
Litigation settlements and expenses
|
0.2
|
%
|
|
1.6
|
|
|
0.6
|
|
|
0.02
|
|
|
—
|
%
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Special charges
|
5.1
|
%
|
|
34.8
|
|
|
2.7
|
|
|
0.47
|
|
|
2.1
|
%
|
|
13.7
|
|
|
4.7
|
|
|
0.13
|
|
||||||
Foreign valuation allowance
|
—
|
%
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
%
|
|
—
|
|
|
18.8
|
|
|
(0.28
|
)
|
||||||
Adjusted Basis
|
16.1
|
%
|
|
$
|
86.5
|
|
|
$
|
25.5
|
|
|
$
|
0.91
|
|
|
15.2
|
%
|
|
$
|
76.6
|
|
|
$
|
22.7
|
|
|
$
|
0.81
|
|
1
Total does not add due to rounding
|
|
Year to Date Ended June 30
|
||||||
|
2017
|
|
2016
|
||||
Cash Flows Provided By (Used In):
|
|
|
|
||||
Operating activities
|
$
|
239.7
|
|
|
$
|
205.4
|
|
Investing activities
|
(369.1
|
)
|
|
(60.3
|
)
|
||
Financing activities
|
137.9
|
|
|
(136.1
|
)
|
||
Effect of exchange rate changes on cash
|
2.5
|
|
|
(2.2
|
)
|
||
Increase in Cash and Cash Equivalents
|
$
|
11.0
|
|
|
$
|
6.8
|
|
Item 3.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS
|
Item 4.
|
CONTROLS AND PROCEDURES
|
Item 1.
|
LEGAL PROCEEDINGS
|
Item 1A.
|
RISK FACTORS
|
Item 2.
|
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
|
Period
|
Total
Number
of Shares
Purchased (1)
|
|
Average
Price Paid
per Share
|
|
Total Number
of Shares
Purchased as
Part of Publicly
Announced Plans or Programs (2)
|
|
Approximate
Dollar Value
of Shares That
May Yet Be
Purchased Under
the Programs (2)
|
||||||
April 1, 2017 - April 30, 2017
|
307
|
|
|
$
|
70.39
|
|
|
—
|
|
|
$
|
34.7
|
|
May 1, 2017 - May 31, 2017
|
6,956
|
|
|
$
|
73.98
|
|
|
—
|
|
|
$
|
34.7
|
|
June 1, 2017 - June 30, 2017
|
1,683
|
|
|
$
|
79.38
|
|
|
—
|
|
|
$
|
34.7
|
|
Total
|
8,946
|
|
|
|
|
—
|
|
|
|
(1)
|
Shares purchased during the quarter ended
June 30, 2017
were in connection with employee payroll tax withholding for restricted and deferred stock distributions.
|
(2)
|
In September 2013, the Board approved an expansion of its previously announced share repurchase authorization to a total of $190.0 million. As of
June 30, 2017
, a cumulative total of
$155.3 million
has been used under this existing authorization. The plan does not have an expiration date and currently there are no plans to terminate this program in the future. However, we do not expect to make additional purchases under this program in fiscal 2017.
|
Item 6.
|
EXHIBITS
|
A.
|
Exhibits
|
10.1*
|
|
Addendum to Employment Agreement between HR Europe B.V. and Francisco Canal Vega, dated July 20, 2017 (addendum to employment contract dated August 27, 2015 between HR Europe B.V. and Francisco Canal Vega)
|
|
|
|
10.2
|
|
Loan and Security Agreement dated as of May 5, 2017, by and among Hill-Rom Finance Company LLC, as borrower, the lenders and group agents from time to time party thereto, The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as administrative agent, and Hill-Rom Company, Inc., as initial servicer (incorporated herein by reference to Exhibit 10.1 to the Form 8-K dated May 5, 2017)
|
|
|
|
31.1
|
|
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
|
31.2
|
|
Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
|
32.1
|
|
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
|
|
32.2
|
|
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
|
|
101.INS
|
XBRL Instance Document
|
|
|
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
|
101.LAB
|
XBRL Extension Labels Linkbase Document
|
|
|
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
HILL-ROM HOLDINGS, INC.
|
|
(Registrant)
|
DATE: July 28, 2017
|
By:
|
|
|
/s/ Steven J. Strobel
|
|
Name:
Title:
|
|
|
Steven J. Strobel
Senior Vice President and Chief Financial Officer
(duly authorized officer and principal financial officer)
|
1.
|
HR Europe B.V.
, a private limited liability company, having its registered office at Hoogoorddreef 15, geb. Amerika, 7e etage, 1101BA Amsterdam, The Netherlands, ("
HR Europe
"), in this matter duly represented by Etienne Claessens, VP Human Resources International.
|
A.
|
The Director is employed by HR Europe since October 1, 2015 for an indefinite period of time;
|
B.
|
The Director is Managing Director pursuant to the Company’s Articles of Association of HR Europe since October 15, 2015, as well as of several other legal entities within the Hill-Rom group of companies;
|
C.
|
Effective June 13, 2017 the Director has been promoted to the position of Senior Vice President and President Global Surgical Solutions (GSS) and has become a member of the Executive Leadership Team;
|
D.
|
An employment contract dated August 27, 2015 is in place between parties, (hereinafter the "
Agreement
");
|
E.
|
Parties agree to alter the Agreement due to the Director’s promotion in accordance with this Addendum (the "
Addendum
").
|
1.1
|
As of June 13, 2017 the Director fulfills the position of Senior Vice President and President Global Surgical Solutions (GSS) and is member of the Executive Leadership Team. The Director will report directly to the Chief Executive Officer of Hill-Rom in Chicago.
|
1.2
|
The Director will perform his work at the Hill-Rom office at Benzstrasse 26, 82178 Puchheim, Germany and will be required to travel substantially and work on location at various Hill-Rom offices in Europe and the United States of America.
|
2.1
|
The Director is entitled to an annual base salary of € 375.000,- gross, including 8% holiday allowance, on a 12 month basis. The salary will be subject to Dutch tax and social security withholdings requirements and paid in twelve equal installments.
|
2.2
|
The Director will continue to be eligible to participate in the Company’s Short-Term Incentive Compensation (STIC) Program with an increased target of 70% of the base gross annual salary. STIC payout is based on achievement of Hill-Rom’s financial objectives as well as the Director’s individual performance objectives. For fiscal year 2017, the Director’s STIC payout will be based on a combination of the STIC target of 40% of the base gross annual salary until June 13, 2017 and the increased STIC target of 70% of the base gross
|
2.3
|
The Director will continue to be eligible to participate in the Company’s Long Term Incentive (LTI) Program with an increased target of 175% of the base gross annual salary. The increased LTI target of 175% will be effective with the November, 2017 annual award. Annual awards will be based on the individual performance of the Director and are subject to CEO and Board approval.
|
2.4
|
The Director is entitled to a Promotion Equity Award of $100,000 and will receive a one-time award of shares of Restricted Stock Units (RSUs) of Hill-Rom Holdings, Inc. subject to the terms and conditions of the stock award agreement. The number of shares was determined based on the stock price on June 6, 2017, the effective date of the award. This award will fully vest on the day following the third anniversary of the effective date of the award.
|
2.5
|
The Director shall be entitled to a maximum reimbursement of $3,000 per calendar year for tax consultation and preparation services.
|
3.1
|
The Director will continue to participate in the pension scheme of HR Europe and HR Europe will pay the Director the amount of € 26,500 annual to ensure internal equity with Director’s ELT cohort. The method an timing of the payments will be determined after consultation with a local tax advisor on an annual basis
|
4.1
|
The post contractual restraints as adopted in the Agreement, including Article 11: Confidentiality and Article 12: Non-Competition, will continue to apply and remain in full force.
|
5.1
|
All other terms and conditions of the Agreement will remain in force.
|
5.2
|
This Addendum is governed by Dutch law.
|
For HR Europe B.V.:
|
|
|
/s/Etienne Claessens
|
|
/s/Francisco Canal Vega
|
Etienne Claessens
|
|
Francisco Canal Vega
|
•
|
The Employer is - briefly stated - engaged in the healthcare industry including, but not limited to, the design, manufacturing, sales, service and rental of hospital beds and stretchers, hospital furniture, medical-related architectural products, specialty sleep surfaces (including therapeutic surfaces), air clearing devices, biomedical and asset management services, as well as other medical-related accessories, devices, products and services;
|
•
|
The Employer is willing to employ the Director as a Managing Director (“
statutair directeur”
) and the Director desires to be employed by the Employer in such capacity based upon the terms and conditions set forth in this Director’s Employment Contract;
|
•
|
The Director will officially be appointed as Managing Director of the Employer by shareholders resolution in accordance with the articles of association of the Employer;
|
•
|
In the course of the employment contemplated under this Director’s Employment Contract it will be necessary for the Director to acquire and maintain knowledge of certain trade secrets and other confidential and proprietary information regarding the Employer as well as any of its parent, subsidiary and/or affiliated entities (hereinafter jointly referred to as the "
Companies
");
|
•
|
Parties acknowledge and agree that the execution of this Director’s Employment Contract is necessary to memorialize the terms and conditions of their employment relationship as well as safeguard against the unauthorized disclosure or use of the Employer's confidential information and to otherwise preserve the goodwill and ongoing business value of the Employer;
|
•
|
Now therefore, in consideration of the Director's employment, the Employer's willingness to disclose certain confidential and proprietary information to the Director and the mutual covenants contained herein as well as other good and valuable consideration, the receipt of which is hereby acknowledged, Parties agree as follows;
|
1.
|
The Director’s Employment Contract will commence on
October 1st, 2015
and is entered into for an indefinite period of time.
|
2.
|
The Director may terminate the Director’s Employment Contract subject to
two months
of notice, and the Employer may terminate the Director’s Employment Contract subject to
four months
of notice. Notice may be given only in writing, taking effect from the end of the calendar month.
|
3.
|
In the event that the Employer terminates the contract by giving notice for reasons other than an urgent reason, (“
ontslag op staande voet wegens een dringende reden
”) within the meaning of article 7:678 of the Dutch Civil Code, the Director will be entitled to his customary benefits during his notice period, as well as a prorated STIC bonus at target in replacement of any other STIC entitlement, to be paid out in the month following the termination date.
|
4.
|
The Director will be entitled to a lump sum severance payment equal to the amount of four gross most recent monthly basic salaries (within the meaning of clause 4 paragraph 1 of this employment agreement) (the “
Severance Payment
”) if:
|
i)
|
the employment agreement is terminated upon the initiative of the Employer other than a) for urgent cause within the meaning of article 7:678 of the Dutch Civil Code, b) in case of illness of more than two years, or c) in case of eligibility for old-age pension act benefits (“AOW-uitkering”); and
|
ii)
|
the Director is appointed as Managing Director (“
statutair directeur
”) by the general meeting of shareholders of the Employer and is still a Managing Director as per the termination date; and
|
iii)
|
the Director will grant the Employer full and final release and discharge of all outstanding obligations under the employment agreement and the termination thereof.
|
5.
|
The Director’s Employment Contract will end in any event without notice being required on the day as per which the Director will be eligible for old-age pension act benefits (“
AOW-uitkering
”).
|
1.
|
The Director will hold the position of Managing Director (“
statutair directeur
”) of the Employer, with the title of
President Europe
. The Director will report to the
SVP & President International
of Employer’s parent company, Hill-Rom Holdings, Inc.
|
2.
|
In the position of Managing Director, the Director will be entrusted with the management of the Employer (in the broad sense of the word). The Director will in his position of Managing Director act in accordance with the obligations arising from this employment agreement, the articles of association of the Employer and Dutch law.
|
3.
|
The Director is obliged to do or refrain from doing all that managing directors in similar positions should do or should refrain from doing. The Director will devote himself, his time and his energy to promoting the interest of the Employer and its subsidiaries and affiliates, without prejudice to any other duties and responsibilities which may be reasonably required by the Employer within the general scope of the Director’s employment. The Director will perform his duties responsibly and with full commitment in accordance with the instructions and directions given on behalf of the Employer.
|
4.
|
The Director covenants that he will also perform duties other than those that are considered his usual duties, if such performance may be reasonably expected from him.
|
5.
|
The Director will be required to perform work for a company affiliated with the Employer, should the Employer so demand.
|
1.
|
The work week will run from Monday to Friday. The working hours amount to 40 hours a week.
|
2.
|
The Director will perform his work at the Employer’s office in Amsterdam, The Netherlands. The Director also undertakes to perform work at a location other than this location if he can reasonably be expected to do so and the interests of both the Employer and the Director will be taken into account in this process.
|
3.
|
The Director covenants that, at the Employer’s request, he will work overtime outside the normal working hours whenever a proper performance of his duties so require. No remuneration will be paid for overtime work.
|
4.
|
Commuting time does not qualify for remuneration, irrespective of whether such commuting time took place during overtime or during working hours.
|
1.
|
The Director will receive a gross basic monthly salary of
€ 25,077.16
on the basis of a 40-hour working week (excluding holiday allowance). The Director’s annual base gross salary will amount to
EUR 325,000
(three hundred twenty five thousand euro), including 8% holiday allowance, on a 12 months basis. The Director will be eligible for a merit increase as per January 1
st
, 2016, and on an annual basis thereafter.
|
2.
|
The annual gross basic annual salary includes 8% holiday allowance, which will be paid out every year in the month of May.
|
3.
|
The Director will participate in the applicable short and long term incentive compensation schemes currently in force, as may be amended from time to time. The granting of the bonus is at the Employer’s discretion. The Director can in no event lay claim to incentive compensation that has not yet been granted. The granting of incentive compensation in any given year or during several years will not create a precedent for any subsequent years. The tax and social security consequences of participation in the short and long term incentive compensation schemes will be at the Director’s expense.
|
•
|
The Director will be eligible for an annual short term incentive compensation award, calculated on a yearly defined pool, linked to the global performances of our group. Based upon a 100% IC pool and the full achievement of the Director’s individual assignment, the Director’s bonus target will represent 40% of his annual base salary. The Director is not entitled to payment of any amount of bonus if at the time of payment he is no longer employed by the Employer and/or disciplinary measures have been taken against the Director, including but not limited to a suspension or a penalty.
|
•
|
The Director will be eligible for an annual long term incentive compensation award which at target is 40 % of his annual base salary. The award is subject to approval by the CEO and Board of Directors. Within 30 days of the Director’s long term incentive grant, he will be provided with a Hill-Rom Holdings, lnc. stock award agreement providing additional details regarding his award.
|
4.
|
The Director will be eligible for professional income tax filing support service by a provider selected by the Employer, during the first year of joining the Employer, i.e. 2015
|
5.
|
The Director will be eligible for relocation support in line with the Employer's relocation policy guidelines
|
1.
|
The Employer will reimburse the Director for expenses directly related to the performance of his work in accordance with the Employer's Business Expense Reimbursement Policy, but only insofar as that reimbursement may be provided tax free and premium free pursuant to the tax and social security legislation in force at any given time. The Employer's Business Expense Reimbursement Policy may be unilaterally amended by the Employer from time to time in accordance with Dutch law.
|
2.
|
A statement of expenses must be submitted to the Employer prior to the end of the month following the month in which the expenses were incurred. Expenses can be claimed upon submission of the original receipt(s), specifying the business-related reason for which they were incurred. The Employer will reimburse the expenses within one month after the Director has claimed them, provided that the statement of expenses is sufficiently itemized, accompanied by the original receipt(s) and approved by the Employer.
|
3.
|
The Employer will provide the Director with a company lease car, or equally valued transportation allowance, of EUR 1,390.00 gross per month during the term of this Director’s Employment Contract. The Director may use the car for private purposes within reasonable limits. The tax consequences of the private use of the car are for the
|
4.
|
Upon relocation, the Employer will provide the Director with a net housing allowance of EUR 2,000.00 per month during the term of this Director’s Employment Contract.
|
1.
|
The Employer will place at the Director’s disposal a mobile phone and laptop, meant for business purposes and reasonable private use.
|
1.
|
The Director will participate in the Employer’s pension scheme. The provisions of the Employer’s pension scheme are laid down in the pension regulations. The Director will receive a copy of the pension regulations upon request. By signing this Director’s Employment Contract, the Director acknowledges to be familiar with and agrees to the Employer’s pension scheme and will comply with all obligations arising from such scheme.
|
2.
|
The Director’s contribution to the pensionable earnings will be withheld from the Director's gross salary.
|
3.
|
The Employer has the right to unilaterally amend the provisions of the pension agreement if the amendment is of such importance to the interests of the Employer that any possible interest of the Director that might be harmed by the amendment should in all reasonableness be superseded.
|
1.
|
The Director will be entitled to twenty five (25) vacation days each calendar year, on the basis of a 40-hour working week. If the Director performed work during only a part of the year, the number of vacation days will be calculated proportionately.
|
2.
|
The Director must timely inform the SVP & President International, in writing, of his wishes with respect to the beginning and end of his vacation period.
|
3.
|
The Director will be required to take vacation days as much as possible in the year in which they are accrued.
|
1.
|
If the Director is unable to perform the agreed work due to illness, he will be obliged to inform the Employer thereof before 9.00 a.m. on the first day of illness, stating the reasons, the expected period of illness and the correct address at which he can be reached during that period. As soon as the Director knows on what day he will be able to resume work, he will inform the Employer thereof immediately.
|
2.
|
If the Director is unfit to perform the agreed work due to illness, he will remain entitled to continued payment of wages for a maximum period of 104 weeks or up to the date of termination of the Director’s Employment Contract if that date is earlier, on the basis of the following conditions:
|
•
|
during the first 52 weeks of illness, the Director remains entitled to 100% of the most recent gross basic salary;
|
•
|
as of the 53
rd
week up to and including the 104
th
week of illness, the Director remains entitled to 70% of the most recent gross basic salary.
|
3.
|
The Director will not be entitled to continued payment of wages during the aforementioned period if he caused the illness intentionally, if the illness ensued from an infirmity about which he gave the Employer false information when he entered into the Director’s Employment Contract, if he causes an obstruction of or delay in the recovery process, or if the Director refuses to perform other suitable work for the Employer or another (possibly affiliated)
|
4.
|
The Employer will be entitled to suspend continued wage payments pursuant to Article 9.1 if the Director does not comply with the Employer’s reasonable instructions, issued in writing, concerning the provision of information that the Employer requires in order to establish the Director’s right to payment of wages.
|
5.
|
If the Director’s occupational disability ensues from an event for which another is liable, the Director must immediately provide the Employer with all of the relevant information and do everything in his power to enable the Employer to exercise its right of recourse within the meaning of Section 6:107a of the Dutch Civil Code (“
Burgerlijk Wetboek”
).
|
1.
|
In accordance with the Dutch Health Care Insurance Act (“
Zorgverzekeringswet”
), the Employer will pay the Dutch Tax and Customs Administration on behalf of the Director the income-related contribution fixed by the government each year.
|
1.
|
Other than for the benefit of the Employer within the scope of the normal work, the Director may neither during the term of the Director’s Employment Contract nor after its termination inform any third party in any form, directly or indirectly, of any particulars concerning or related to the business conducted by the Employer or its affiliated companies, regardless of whether such information includes any reference to its confidential nature or ownership and regardless of how the Director learned of the particulars.
|
2.
|
Other than for the benefit of the Employer within the scope of the normal work, the Director may also not copy, compile, merge, assemble or process information, products or systems of the Employer or disassemble, reproduce or decompile the source code of the computer software that is included in those products or systems or otherwise available on the Employer’s premises or attempt to deduce the source code of such software in any other manner.
|
3.
|
Notwithstanding the provisions of Section 7:650(3), (4) and (5) of the Dutch Civil Code, if the Director violates the confidentiality clause contained in Articles 14.1 and 14.2, he will forfeit to the Employer an immediately due and payable penalty of EUR 30,000.00 for each violation as well as a penalty of EUR 2,000.00 for each day that the violation continues, without prejudice to the Employer’s right to claim specific performance of the Director’s Employment Contract in addition to that penalty and full compensation instead of that penalty.
|
1.
|
For a period of 12 months after the termination of the Director’s Employment Contract (or day or notice in case the Employer terminates the agreement), the Director may not, without the Employer’s prior written consent, alone or with others, whether or not for consideration, in any way whatsoever:
|
a.
|
perform work that competes with the business operations of the Employer or its group companies;
|
b.
|
perform work for any business that competes with the Employer or its group companies; examples of such direct competitors are (but not limited to) Linet, Arjo Huntleigh, Stiegelmeyer, Paramount, Stryker, Handicare, Wissner, Guldmann, Heinicare, Remedica, and Etac;
|
c.
|
Article 12.1.b explicitly aims at those parts of the business of any of these, or other, organizations that directly or indirectly compete with the business operations of the Employer at the time of the termination.
|
d.
|
incorporate, conduct or cause the conduct of a business that competes with the Employer or its group companies or take any interest in such business;
|
e.
|
maintain contact with or perform work for or with business relations of the Employer or its group companies, regardless of whether such contact is maintained or work is performed directly or indirectly or at the Director’s own expense or at the expense of third parties; ‘business relations’ are all natural persons with whom and legal entities with which the Employer or its group companies maintained business
|
f.
|
induce employees or contractors of the Employer or its group companies, either directly or indirectly, to terminate their Director’s Employment Contract or contract for services with the Employer or its group companies; or
|
g.
|
with respect to contracts between the Employer or its group companies and suppliers to supply goods or services: directly or indirectly thwart the supply of such goods or services or induce a supplier, either directly or indirectly, to discontinue or refuse the supply of such goods or services to the Employer or its group companies;
|
2.
|
Notwithstanding the provisions of Section 7:650(3), (4) and (5) of the Dutch Civil Code, if the Director violates the non-competition clause contained in paragraph 1 of this article, he will forfeit to the Employer an immediately due and payable penalty of EUR 30,000.00 for each violation as well as a penalty of EUR 2,000.00 for each day that the violation continues, without prejudice to the Employer’s right to claim specific performance of the Director’s Employment Contract in addition to that penalty and full compensation instead of that penalty.
|
3.
|
When the duration of the employment is less than 12 months, the non-competition period after the termination, referred to in the first sentence of that article, will be equal to the duration of the Director’s Employment Contract in months.
|
4.
|
During the first four months of the period during which the Director is bound to the prohibition of competition within the meaning of clause 12 paragraph 1, under a, b, c and d of this employment agreement (the “
Prohibition Period
”), the Employer will pay to the Director a compensation equal to 100 percent (100%) of the Director’s most recent gross monthly basic salary (within the meaning of clause 4 paragraph 1 of this employment agreement) (the “
Compensation
”). The Compensation will be paid to the Director in four equal instalments at the end of every month.
|
1.
|
During the term of the Director’s Employment Contract, the Director must refrain from undertaking or holding any sidelines or additional posts, such as committee work, or managerial or other activities for associations, foundations or other organizations of an idealistic, cultural, sporting, political or other nature, whether or not for consideration, without the Employer’s prior written consent, regardless of whether the Employer is either partly or fully aware of such activities. This will be limited to payable sidelines or posts, or if these sidelines or additional posts obstruct the Director’s work for the Employer.
|
2.
|
Without prejudice to the foregoing clause, Employer consents to the fact that the Director currently holds and may continue to hold the external positions attached to this contract (see Annex A), under the condition that all costs associated with these positions are not for the account of Employer and that these positions do not obstruct the Director’s work for the Employer
|
1.
|
The Employer will be entitled to process personal data relating to the Director within the framework of performing the Director’s Employment Contract and/or provisions ensuing from or in relation to the employment relationship.
|
2.
|
The Employer uses the Director’s personal data for the purpose of its personnel and payroll records and to comply with its statutory obligations, including but not limited to withholding wage tax and social security contributions, to maintain and improve effective personnel records, including payroll records and compliance with statutory obligations, to administer Director benefits, including insurance and pension provisions, and to administer programs
|
3.
|
For these purposes and to comply with its statutory obligations, the Employer may also transfer the Director’s personal data to third parties and other companies of the Employer located in countries inside and outside the European Union. If applicable, the Employer will apply for the required permits and notify the data processing to the relevant authorities.
|
4.
|
The Employer will process the personal data in a proper and careful manner. Furthermore, the Employer will take appropriate technical and organizational measures to sufficiently safeguard personal data and to preserve the confidential nature of the Director’s personal data, regardless of whether such data are processed in Europe, the United States or elsewhere.
|
5.
|
The Director will be entitled to contact the Employer with a reasonable request to review, correct, supplement, delete or block his personal data. Furthermore, the Director will notify the Employer of any changes in his personal data in a timely fashion.
|
6.
|
In accordance with the Dutch Personal Data Protection Act (“Wet
Bescherming Persoonsgegevens
”), the Employer will not store the personal data for longer than is necessary for the purposes of the processing.
|
1.
|
The Director will be obliged to observe due care in handling any company documents, in any form whatsoever, and any company equipment made available to him. ‘Company equipment’ includes in any event the access pass/key, laptop, mobile phone and credit card.
|
2.
|
Upon termination of the Director’s Employment Contract, the Director will be obliged to return all company documents and company equipment to the Employer in good condition. Furthermore, the Director will be obliged to return such company property should the Employer so demand, for example in the event that he does not perform work due to occupational disability or has been placed in non-active service.
|
1.
|
All intellectual property rights, including but not limited to patent rights, design rights, copyrights, neighboring rights, database rights, trademark rights, chip rights, trade name rights and Know-How (as defined in paragraph 2 of this article), ensuing in the Netherlands or abroad, during the term of this Director’s Employment Contract or after its termination, from the work performed by the Director under this Director’s Employment Contract (the ‘Intellectual Property Rights’) will exclusively vest in the Employer.
|
2.
|
‘Know-How’ is defined as any and all trade secrets, secret formulas, inventions, designs, standards, technical and other data or information, processes, methods, draft materials and business methods and any and all related information, knowledge, details, commercial practices and improvements.
|
3.
|
Insofar as any Intellectual Property Rights are not vested in the Employer by operation of law, the Director covenants that he will transfer to the Employer, should the Employer so demand, and, insofar as possible, hereby transfers those rights to the Employer, which transfer is hereby accepted by the Employer.
|
4.
|
Insofar as any Intellectual Property Rights are incapable of being transferred from the Director to the Employer, the Director hereby grants the Employer the exclusive, royalty-free, worldwide, perpetual right, with the right to grant sublicenses, to use those Intellectual Property Rights in the broadest sense, which right is hereby accepted by the Employer.
|
5.
|
Insofar as any personal rights vest in the Director and insofar as permitted by law, the Director hereby waives all of his personal rights, including but not limited to the right to have one’s name stated pursuant to the Dutch Copyright Act of 1912 (
Auteurswet 1912
).
|
6.
|
The Director will promptly disclose to the Employer all works, inventions, results, information and Intellectual Property Rights that ensue from his work under this Director’s Employment Contract and/or that are in any way relevant to the creation, protection and/or enforcement of the Intellectual Property Rights.
|
7.
|
During the term of this Director’s Employment Contract and after its termination, the Director will perform all acts that are necessary to register the Intellectual Property Rights in the Employer’s name with any competent authority in the world.
|
8.
|
If the Director is unable to provide the cooperation referred to in paragraphs 3 and 7 of this article for any reason, he hereby grants the Employer an irrevocable power of attorney to represent him with respect to the transfer and registration of the Intellectual Property Rights referred to in paragraphs 3 and 7 of this article, respectively.
|
9.
|
The Director acknowledges that his salary includes reasonable compensation for the loss of intellectual property rights.
|
10.
|
The Director may not use the Intellectual Property Rights or the ensuing results for any purpose other than the performance of his work under this Director’s Employment Contract.
|
11.
|
The Director guarantees that the results of his work and/or activities under this Director’s Employment Contract do not infringe upon any rights (including intellectual property rights) of third parties and that they are not unlawful vis-à-vis third parties in any other manner. The Director will indemnify the Employer against any and all damage and costs ensuing from claims brought by third parties in that respect.
|
12.
|
The Employer will not be liable for damage incurred by the Director in connection with the Employer’s use of inventions, designs, works, programs, documents, data, names, signs, Know-How, materials or other achievements that the Director discloses to the Employer during the term of this Director’s Employment Contract and that (i) fall outside of the scope of this Director’s Employment Contract or (ii) were created or developed prior to the conclusion of this Director’s Employment Contract.
|
13.
|
If this Director’s Employment Contract is terminated, the Articles governing the Intellectual Property Rights set out above will remain in effect after the termination of the Director’s Employment Contract.
|
1.
|
This Director’s Employment Contract will not be governed by the provisions of any Collective Bargaining Agreement.
|
1.
|
In accordance with Section 7:613 of the Dutch Civil Code, the Employer will be authorized to unilaterally amend the conditions contained in this Director’s Employment Contract if and insofar as it has a weighty interest in doing so that is of such a nature that the Director’s interests, insofar as they are harmed by the amendment, in all reasonableness and fairness must yield to the Employer’s interest.
|
1.
|
This Director’s Employment Contract will be governed by Dutch law.
|
Product / service:
|
Software and service, specializing in the control and management of large and complex work forces
|
Product / service:
|
R&D company dedicated to the development of systems for the standardization and optimization of cell culture (bio-reactors, culture media and software
|
Date: July 28, 2017
|
|
|
|
/s/ John J. Greisch
|
|
John J. Greisch
|
|
President and Chief Executive Officer
|
|
Date: July 28, 2017
|
|
|
|
/s/ Steven J. Strobel
|
|
Steven J. Strobel
|
|
Senior Vice President and Chief Financial Officer
|
|
(1)
|
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Corporation.
|
(1)
|
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Corporation.
|